TScan Therapeutics, Inc. (TCRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TScan Therapeutics, Inc. on November 25, 2025. The filing discloses the Board of Directors' approval of a new employee retention program designed to support the advancement of the Company's pivotal trial for its lead candidate, TSC-101.
Key Financial Metrics
The filing does not provide updated revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements.
Material Changes and Executive Compensation
The Board approved a Retention Program for three key officers: Gavin MacBeath (CEO), Jason A. Amello (CFO), and Chrystal Louis (CMO). The program includes cash awards and potential equity grants contingent upon the advancement of the TSC-101 pivotal trial (the "Milestone").
- Cash Awards:
- CEO: $399,000
- CFO: $170,000
- CMO: $250,000
- Payment Terms: 50% of cash awards are payable upon achievement of the Milestone; the remaining 50% is payable on the first anniversary of the Milestone.
- Equity Awards (RSUs):
- CEO: 1,000,000 RSUs
- CFO: 270,000 RSUs
- CMO: 650,000 RSUs
- Equity Vesting: RSUs are granted upon achievement of the Milestone. Vesting occurs 25% on the second anniversary of the Milestone and 75% upon the earlier of the completion of the pivotal trial or the fourth anniversary of the grant date.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the Retention Program and the Company's expectations for the TSC-101 pivotal trial. The Company explicitly disclaims any obligation to update these statements. Risks include the substantial uncertainties associated with clinical trial outcomes and the potential for financial results to differ from expectations.
Investor Verification Checklist
- Verify the specific definition and criteria for the "Milestone" (advancement of the TSC-101 pivotal trial) in the underlying award agreements.
- Confirm the Company's current cash position to assess the ability to fund the potential $819,000 in immediate cash awards upon Milestone achievement.
- Review the Company's 2021 Equity Incentive Plan to confirm sufficient shares are available for the potential grant of 1,920,000 RSUs.
- Monitor upcoming clinical trial updates for TSC-101 to determine the likelihood of triggering these compensation events.